Saskia N. De Wildt, Netherlands

Saskia de Wildt studied Medicine at Maastricht University. She performed her PhD research at Erasmus University Sophia Children’s Hospital Rotterdam on Developmental aspects of midazolam metabolism. She next trained in pediatrics and pediatric intensive care, also in Rotterdam and at the Hospital of Sick Children in Toronto, while also obtaining the American and Dutch Board of Clinical Pharmacology certification as clinical pharmacologist. Since May 2016, she is appointed full professor of Clinical Pharmacology, combining this appointment with clinical care in the Pediatric Intensive Care at Radboud University in Nijmegen. She has published over 100 peer-review international papers and received over 3.5 million euros PI research funding. Her research has been largely supported by ZonMW and EU FP7 grants, which aim to better understand the impact of age, disease and genetics on drug disposition and to individualize drug dosing in children, with a focus on pain&sedation and AKI. She participates in two EU H2020 grants aimed to develop EU-wide infrastructure to study drugs in children. Saskia de Wildt is director of the Dutch Knowledge Center for Pharmacotherapy in Children and as such responsible for the Dutch Pediatric Drug Handbook (‘kinderformularium.nl’)

Author Of 1 Presentation

CONFERENCE CALENDAR

WHICH PARAMETERS SHOULD BE CONSIDERED AS OPTIMAL OUTCOME IN DRUG STUDIES

Presenter

Saskia N. De Wildt, Netherlands

Authors

Saskia N. De Wildt, Netherlands

Room

Trakl Hall

Date

20.06.2019

Session Time

09:10 - 10:40

Session Name

Primary endpoints in drug trials

Duration

20 Minutes

Abstract
Presentation files

Abstract

Background

Children are not small adults, hence outcomes to be used in clinical studies may also be different. Moreover, with the increased attention for long-term effects post PICU admission our recent focus on short-term outcomes may need to be revisited

Objectives

1. To present frequently used outcomes in PICU trials

2. To discuss the importance and strategy to choose relevant outcomes and how this may affect trial design

Methods

.Present examples of outcomes used in pediatric intensive care drug studies, including biomarkers, clinical outcomes, patient reported outcomes, pharmacokinetics

Results

Outcomes used in drug studies are for example: percentage of time sedated, ventilator free days, incidence of bacterial infections, quality of life

Conclusion

This presentation will not only focus on outcomes in prospective clinical trials, but will also provide guidance to study design of prospective cohort studies and retrospective studies and the strategy to choose the most optimal outcome

Ultimately, aclear understanding of the challenges and importance to choose the right outcome measure will improve the impact of your research!

Hide

Presentation files

de wildt 2019 ESPNIC endpoints 20.06.2019 10:33